Endurance Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Endurance Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$873	–	660
2022 Q3	$1K	Hold	100	–	–	﹤0.01%	604
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	616
2022 Q1	$1K	Hold	100	–	–	﹤0.01%	633
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	619
2021 Q3	$1K	Hold	100	–	–	﹤0.01%	624
2021 Q2	$0	Hold	100	–	–	﹤0.01%	650
2021 Q1	$1K	Hold	100	–	–	﹤0.01%	634
2020 Q4	$1K	Hold	100	–	–	﹤0.01%	608
2020 Q3	$1K	Hold	100	–	–	﹤0.01%	608
2020 Q2	$1K	Hold	100	–	–	﹤0.01%	599
2020 Q1	$1K	Hold	100	–	–	﹤0.01%	558
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	510
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	516
2019 Q2	$1K	Hold	100	–	–	﹤0.01%	466
2019 Q1	$2K	Hold	100	–	–	﹤0.01%	451
2018 Q4	$2K	Hold	100	–	–	﹤0.01%	448
2018 Q3	$2K	Hold	100	–	–	﹤0.01%	463
2018 Q2	$2K	Hold	100	–	–	﹤0.01%	472
2018 Q1	$2K	Sell	100 -600	-86%	-$11.7K	﹤0.01%	494
2017 Q4	$13K	Sell	700 -23,252	-97%	-$350K	﹤0.01%	390
2017 Q3	$422K	Sell	23,952 -4,225	-15%	-$95.1K	0.07%	133
2017 Q2	$936K	Sell	28,177 -3,500	-11%	-$108K	0.16%	95
2017 Q1	$1.02M	Sell	31,677 -11,275	-26%	-$385K	0.18%	95
2016 Q4	$1.56M	Sell	42,952 -32,901	-43%	-$1.31M	0.28%	79
2016 Q3	$3.42M	Buy	75,853 +925	+1%	+$48.3K	0.61%	50
2016 Q2	$3.76M	Buy	74,928 +5,200	+7%	+$277K	0.71%	44
2016 Q1	$3.73M	Buy	69,728 +775	+1%	+$45.5K	0.52%	45
2015 Q4	$4.53M	Sell	68,953 -525	-0.8%	-$32.4K	0.86%	38
2015 Q3	$4.11M	Buy	69,478 +600	+0.9%	+$38.9K	0.72%	42
2015 Q2	$4.07M	Sell	68,878 -518	-0.7%	-$32K	0.68%	45
2015 Q1	$4.32M	Buy	69,396 +5,151	+8%	+$299K	0.75%	40
2014 Q4	$3.69M	Buy	64,245 +5,024	+8%	+$280K	0.66%	47
2014 Q3	$3.18M	Buy	59,221 +449	+0.8%	+$23.8K	0.59%	49
2014 Q2	$3.08M	Buy	58,772 +4,424	+8%	+$226K	0.51%	55
2014 Q1	$2.87M	Buy	+54,348	New	+$2.51M	0.56%	55

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Endurance Wealth Management's TEVA Position: Q4 2022 in Review

Endurance Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2022, closing a stake of 100 shares — an estimated $873 sold.

Endurance Wealth Management first reported a position in TEVA in Q1 2014 and held it in 35 quarters. The position peaked at $4.53M in Q4 2015. 421 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

Endurance Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Endurance Wealth Management sold 100 Teva Pharmaceuticals shares in Q4 2022, an estimated $873.
Endurance Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 35 quarters.
Endurance Wealth Management's Teva Pharmaceuticals position peaked at $4.53M in Q4 2015.
421 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2022.

Based on Endurance Wealth Management's 13F filing for Q4 2022, filed 1 Feb 2023.